Other News To Note
Wednesday, February 16, 2011
Ceregene Inc., of San Diego, reported gene transfer can provide targeted expression of a neurotrophic factor such as neurturin to restore and preserve dying neurons. The research has significance for Parkinson's disease. Ceregene's neurotrophic therapy, CERE-120, is in clinical trials for advanced Parkinson's disease. The results were published in the current issue of Movement Disorders.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.